CD274 and gastric cancer: In addition, the efficacy and safety of perioperative trastuzumab, PD-(L)1 blockade, and chemotherapy in patients with potentially resectable HER2-positive GC are being investigated in several ongoing phase II trials (10, 11, 23), and the pCR rates range from 31.3% to 42.9% according to the preliminary results, as shown in Table 4.